A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

NCT02000947 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

459

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
Non-small Cell Lung Cancer
Lung Cancer

Interventions

DRUG: MEDI4736
DRUG: Tremelimumab
DRUG: tremelimumab

Sponsor

MedImmune LLC